Ua hoʻokumu ʻo Hackensack University Medical Center i kahi papahana kiaʻi hou e nānā i nā poʻe i pilikia nui no ka hoʻomohala ʻana i ka maʻi maʻi pancreatic.
ʻO ka IMMray® PanCan-d Test ka hoʻāʻo koko mua ma ka mākeke i hoʻolaʻa ʻia no ka ʻike mua ʻana o ka ʻohana a i ʻole ka pancreatic ductal adenocarcinoma (PDAC).
E loaʻa i nā poʻe maʻi i kūpono ka hoʻāʻo kiʻi a me kahi hōʻike biomarker hou e ana i ka pane ʻana o ka ʻōnaehana pale i ka maʻi pancreatic i loko o ke koko.
"ʻIke ʻia ka maʻi maʻi ma mua, ʻoi aku ka maikaʻi o ka mālama ʻana," wahi a Rosario Ligresti, MD, ke poʻo o Gastroenterology ma Hackensack University Medical Center, kahi National Pancreas Foundation Center of Excellence mai 2013, kahi i hāʻawi ʻia ai kēia hana hou ma ke ʻano he ʻāpana. ʻO ka papahana nānā kiʻekiʻe o ka haukapila no ka maʻi maʻi pancreatic.
ʻO ka mea pōʻino, hōʻike nā haʻawina e pili ana i kahi hapaha o ka poʻe i kūpono no ka nānā ʻana i ka pilikia nui e hoʻohana pono iā ia, akā manaʻo ʻo Kauka Ligresti e lilo kēia hōʻike koko hou i mea hoʻololi pāʻani.
"ʻO ka maʻi maʻi pancreatic, kekahi o nā mea make loa o nā maʻi maʻi, he paʻakikī ke ʻike i ka wā mua, i kahi manawa e hiki ai ke ʻoki ʻoki ʻana, ʻo ka lāʻau lapaʻau wale nō," wahi a Dr. Ligresti. "Ua hōʻike ʻia kēia hoʻāʻo hou e ʻike i ka maʻi maʻi pancreatic ma mua o nā maʻi maʻi kiʻekiʻe, me ka pahuhopu o ka hopu ʻana ma mua o ka loaʻa ʻana o ka manawa e laha i nā ʻiʻo ʻē aʻe."
ʻO wai ka mea i manaʻo ʻia he pilikia nui?
Hiki ke holo i ka ma'i 'a'ai pancreatic i loko o ka 'ohana a/a i 'ole e pili ana me nā ma'i ma'i e ho'onui ai i ka pilikia o ka ma'i 'a'ai 'ē a'e. Kapa ʻia kēia maʻi maʻi pancreatic ʻohana a loaʻa nā manawa i nā kaikaina, nā mākua a me nā kūpuna ma o nā hanauna o kou ʻohana i kēia manawa. Hiki iā ʻoe a me kou ʻohana ke piʻi aʻe ka pilikia inā 2 a ʻoi aku paha nā ʻohana degere mua a i ʻole 3 mau lālā o ka ʻohana i loaʻa i ka maʻi maʻi pancreatic.
He aha ke kūlana o ka mālama ʻana i kēia manawa?
I kēia manawa, hana ʻia ka nānā ʻana i ka pancreas no ka maʻi kanesa me ka hoʻohana ʻana i ka MRI a i ʻole endoscopic ultrasound (EUS). He ho'āʻo kūikawā kēia e pili ana i kahi endoscope a me ka ultrasound high-frequency e kiʻi pololei i ka pancreas. Hana ʻia nā hoʻāʻo ʻana i kēlā me kēia makahiki a loaʻa iā lāua nā pono a me nā pōʻino. Hiki i ka MRI ke paʻakikī, pipiʻi a hoʻopau manawa. Hoʻokomo ka EUS i kahi endoscopy liʻiliʻi-invasive a koi i ka hoʻokē ʻai a me ka hoʻomaha. Ke hana nei ʻo Hackensack University Medical Center i ka nānā ʻana i ka pancreas ma kēia ʻano no nā makahiki he nui. Ma mua o kēia manawa, ʻaʻohe hoʻāʻo koko kūikawā a pololei paha i loaʻa ma ke kālepa e ʻae i ka nānā ʻana i ka maʻi maʻi pancreas.
ʻO wai ka mea kūpono no kēia nānā ʻana i ka maʻi maʻi pancreatic hou?
He mea koʻikoʻi ka nānā ʻana i ka maʻi ʻaʻai pancreas ma nā pūʻulu pilikia kiʻekiʻe. ʻO kēlā me kēia maʻi i ʻoi aku ma mua o ka makahiki 18 me:
• Hoʻololi BRCA
• Cystic Fibrosis
• Familial Adenomatous Polyposis (FAP)
• ʻO ka ʻohana Atypical Multiple Mole Melanoma (FAMMM)
• ʻO ka maʻi maʻi ʻaʻai ʻokoʻa nonpolyposis hereditary (HNPCC) a i ʻole Lynch Syndrome
• ʻO ka maʻi maʻi maʻi maʻi
• ka hoʻololi ʻana o PALB2
• Peutz-Jeghers Syndrome
• Mo'olelo 'ohana no ka ma'i 'a'ai ma'i pancreatic i 'elua mau 'ohana o ke degere mua
He aha ka protocol screening?
E loaʻa i nā poʻe maʻi kahi kūkākūkā piha me Dr. Ligresti. E loaʻa iā lākou ka hōʻike IMMray PanCan-d a me kahi MRI a i ʻole EUS i hana ʻia. Ke loaʻa nā hopena a pau, e hui pū lākou me Kauka Ligresti e nānā iā lākou a me ka hoʻolālā no ka nānā mau ʻana. Hana ʻia kēia i kēlā me kēia makahiki.
No ke aha he mea nui ka ʻike mua ʻana i ka maʻi maʻi pancreatic? Hoʻomaka wale nā hōʻailona me ka maʻi hope loa, no laila, ʻike ʻia ka hapa nui o ka maʻi maʻi pancreatic i ka wā hope i ka wā ʻoi aku ka maikaʻi o ka mālama ʻana.
ʻO wai ka pilikia no ka hoʻomohala ʻana i ka maʻi maʻi pancreatic? ʻO ka ʻike ʻana i nā poʻe maʻi e pili ana i ka hoʻomohala ʻana i ka maʻi ma muli o ka ʻike ʻia ʻana o ka genetic mutations a i ʻole ka mōʻaukala ʻohana o ka maʻi maʻi pancreatic hiki ke koʻikoʻi no ka ʻike mua ʻana. Hōʻike nā pūʻulu liʻiliʻi kiʻekiʻe i ka hapa nui o nā hihia āpau o ka maʻi maʻi pancreatic.
Pehea ka hana ana o keia hoao hou? Hoʻopili ka IMMray PanCan-d i 9 biomarkers i ka serum e ʻike ai i ka pancreatic ductal adenocarcinoma (PDAC), ke ʻano maʻamau o ka maʻi maʻi pancreatic. Hoʻokomo ʻia nā biomarkers i nā kaʻina cellular he nui e pili ana i ka metabolism, ka ʻāʻī a me ka hōʻino / hoʻoponopono ʻana o ka ʻiʻo, me CA19-9, i loko o ka assay. Ana ʻia ka pane ʻana o kahi laʻana i kēlā me kēia biomarker a laila hoʻohui ʻia me ka hoʻohana ʻana i kahi algorithm e hoʻoholo ai i kahi hopena hoʻāʻo o "High-Risk Signature Present", "Negative for High-Risk Signature", a i ʻole "Borderline".
Hana Ho'āʻo: Ma kahi paʻi hou ʻia e Brand et al i paʻi ʻia ma Clinical and Translational Gastroenterology, ua hōʻike ka hōʻike IMMray PanCan-d i kahi sensitivity o 92% a me kahi kikoʻī o 99% i ka ʻike ʻana i ka pancreatic ductal adenocarcinoma (PDAC) me ka hoʻohana ʻana i ka serum. Ua hiki i ka IMMray PanCan-d hōʻike ke ʻike i ka Stage I & II PDAC me 89% sensitivity a me 99% kikoʻī.
He aha e lawe ʻia mai kēia ʻatikala:
- In a recent peer-reviewed publication by Brand et al published in Clinical and Translational Gastroenterology, the IMMray PanCan-d test demonstrated a sensitivity of 92% and a specificity of 99% in….
- You and your family may be at an increased risk if 2 or more first-degree relatives or at least 3 members of the family have been diagnosed with pancreatic cancer.
- A sample’s response to each biomarker is measured and then combined using an algorithm to determine a test result of “High-Risk Signature Present”, “Negative for High-Risk Signature”, or “Borderline”.
